Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyobacteriophage polyvalent
- Development stage
- Unknown
- Lead developer
- Microgen
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravesical, Oral, Rectal, Topical, Vaginal
01
Overview
Sextaphage (pyobacteriophage polyvalent) is a commercial polyvalent bacteriophage cocktail developed and manufactured by the Russian company Microgen (a subsidiary of Nacimbio, which is part of Rostec). It consists of sterile purified filtrates of phagolysates from six major bacterial pathogens: *Staphylococcus* spp., *Streptococcus* spp., *Proteus* (including *P. vulgaris* and *P. mirabilis*), *Pseudomonas aeruginosa*, enteropathogenic *Escherichia coli*, and *Klebsiella pneumoniae*. Sextaphage is designed to specifically target, infect, and lyse these bacterial pathogens, making it a therapeutic option for the treatment and prevention of various purulent-inflammatory, urogenital, enteric, and respiratory infections, particularly those caused by multidrug-resistant (MDR) strains. It can be administered orally, topically, or intracavitarily.
- Brand names
- PurofagSextafagSextaphage
- Other names
- polyvalent pyobacteriophagepurified polyvalent pyobacteriophagepyobacteriophagepyobacteriophage polyvalent
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on pyobacteriophage polyvalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyobacteriophage polyvalent.